|Dr. Robert J. Cobuzzi Jr.||Pres, CEO & Director||1.23M||N/A||1965|
|Mr. William Karl Hornung||Chief Financial Officer||450.68k||N/A||1969|
|Mr. William Robert Elder J.D.||Gen. Counsel & Corp. Sec.||338.36k||N/A||1983|
|Dr. Christopher D. Galloway M.D.||Chief Medical Officer||539.59k||N/A||1971|
|Dr. David Randolph Jones M.D.||Sr. Medical Advisor||N/A||N/A||1963|
|Ms. Suzanne Cassidy||Sr. Director & Head of Quality Assurance||N/A||N/A||N/A|
|Dr. Jennifer Llewelyn Ph.D.||Sr. Director & Head of CMC||N/A||N/A||N/A|
|Ms. Kelly Hoy||Director of Project Management||N/A||N/A||N/A|
|Mr. Harry Cook||VP of Clinical Operations||N/A||N/A||N/A|
|Mr. Douglas Gravatt||Sr. Consultant for Manufacturing||N/A||N/A||N/A|
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
Diffusion Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.